In accordance with the guidelines of conflict of interest of the Council Affairs Committee of the American Heart Association, certain presenters have indicated that they have a relationship that, in the context of the subject of their presentation, could be perceived as a real or apparent conflict of interest. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations.

Arthur M. Feldman, MD, PhD
A signed disclosure form had not been received from this faculty member at the time this material was posted.

Lars Rydén, MD
Nothing to disclose.

Finn Waagstein, MD, PhD
A signed disclosure form had not been received from this faculty member at the time this material was posted.

Mariell Jessup, MD
Nothing to disclose.

John C. Burnett, Jr., MD
A signed disclosure form had not been received from this faculty member at the time this material was posted.

James B. Young, MD
Research funding from AstraZeneca, Merck, SmithKline Beecham, Pfizer, Medtronics.

John J.V. McMurray, MD
Steering Committee-AstraZeneca, Novartis.

© 1999 American Heart Association, Inc. and Prous Science. All rights reserved. Unauthorized use prohibited.

The information contained in this American Heart Association Web site is not a substitute for medical advice or treatment, and the Association recommends consultation with your doctor or health care professional.